

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

**SUPPLEMENTAL ANNOUNCEMENT REGARDING THE GRANT OF
SHARE OPTIONS AND RESTRICTED SHARE UNITS**

Reference is made to the announcement issued by CANbridge Pharmaceuticals Inc. (the “**Company**” and together with its subsidiaries, the “**Group**”) dated January 12, 2026 regarding the grant of Share Options and Restricted Share Units (the “**January Announcement**”). Unless otherwise defined, terms used in this announcement shall have the same respective meanings as those defined in the January Announcement.

The Company would like to provide more information on the two Service Provider Option Grantees and the two Service Provider RSU Grantees, who are the same two grantees. One of the Service Providers provides development strategy advice to the Group (“**Service Provider 1**”), while the other Service Provider provides regulatory advice to the Group in respect of regulatory approval for drugs (“**Service Provider 2**”).

Given the long term support which Service Provider 1 provides in respect of the Group’s R&D strategies and activities and the consulting service which Service Provider 2 provides to the Group during the regulatory approval process of the Group’s drugs, the Board believes that granting of Share Options and RSUs to them is in line with the purpose of the respective schemes which is to align the interests of those Service Providers who provide services on a continuing or recurring basis and which are in the interests of the long-term growth of the Group. These grants reflect the long-term service they have been providing to the Group and the importance of such services in the business, growth and development of the Group.

Save for the above, the Company does not have further information to supplement the January Announcement.

By Order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, February 20, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Zhao Wei and Mr. Wang Tingwei as non-executive Directors, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.